Abstract
Primary Progressive Aphasia (PPA) is a neurodegenerative syndrome characterized by a gradual dissolution of language, but relative sparing of other cognitive domains during the initial stages of the disease. Research has led to substantial progress in understanding the clinical characteristics, genetics, and neuropathology of this syndrome. This article reviews the clinical criteria for diagnosing PPA, discusses the utility of defining the mild cognitive impairment (MCI) stage of PPA, and highlights some of the more recent research advances particularly in the area of pathology and genetics.
Keywords: Frontotemporal dementia, dementia, anomia, semantic dementia, progressive nonfluent aphasia, primary progressive aphasia, frontotemporal lobar degeneration
Current Alzheimer Research
Title: Clinical Trajectories and Biological Features of Primary Progressive Aphasia (PPA)
Volume: 6 Issue: 4
Author(s): E. J. Rogalski and M. M. Mesulam
Affiliation:
Keywords: Frontotemporal dementia, dementia, anomia, semantic dementia, progressive nonfluent aphasia, primary progressive aphasia, frontotemporal lobar degeneration
Abstract: Primary Progressive Aphasia (PPA) is a neurodegenerative syndrome characterized by a gradual dissolution of language, but relative sparing of other cognitive domains during the initial stages of the disease. Research has led to substantial progress in understanding the clinical characteristics, genetics, and neuropathology of this syndrome. This article reviews the clinical criteria for diagnosing PPA, discusses the utility of defining the mild cognitive impairment (MCI) stage of PPA, and highlights some of the more recent research advances particularly in the area of pathology and genetics.
Export Options
About this article
Cite this article as:
Rogalski J. E. and Mesulam M. M., Clinical Trajectories and Biological Features of Primary Progressive Aphasia (PPA), Current Alzheimer Research 2009; 6 (4) . https://dx.doi.org/10.2174/156720509788929264
DOI https://dx.doi.org/10.2174/156720509788929264 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Drug Delivery & Formulation Anti-Inflammatory Agents in Parkinsons Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Interactions of Ginkgolides A and B with a Recombinant Human Prion Protein
Protein & Peptide Letters Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Herb-Drug Interactions in Neurological Disorders: A Critical Appraisal
Current Drug Metabolism Microglia-Neuron Interaction in Inflammatory and Degenerative Diseases: Role of Cholinergic and Noradrenergic Systems
CNS & Neurological Disorders - Drug Targets The Role of the Cell Surface LRP and Soluble LRP in Blood-Brain Barrier Aβ Clearance in Alzheimers Disease
Current Pharmaceutical Design Neuroprotective Effect of β-secretase Inhibitory Peptide from Pacific Hake (Merluccius productus) Fish Protein Hydrolysate
Current Alzheimer Research Amyloid β-Peptide: The Inside Story
Current Alzheimer Research Lenticulostriate Artery and Lenticulostriate-artery Neural Complex: New Concept for Intracerebral Hemorrhage
Current Pharmaceutical Design Astrocytes Exert and Control Immune Responses in the Brain
Current Immunology Reviews (Discontinued) Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Inflammatory and Cell Death Pathways in Brain and Peripheral Blood in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Use and Safety of Calcium Channel Blockers in Obstetrics
Current Medicinal Chemistry Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Impaired Neurovascular Coupling in the APPxPS1 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Neuroprotective Properties of Erythropoietin in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Ketogenic Diets in the Treatment of Epilepsy
Current Pharmaceutical Design